BCI
UTHR icon

Brinker Capital Investments’s United Therapeutics UTHR Stock Holding History

Brinker Capital Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Sell
4,176
-64
-2% -$36K 0.02% 730
2026
Q1 		$2.51M Sell
4,240
-332
-7% -$165K 0.02% 645
2025
Q4 		$2.23M Buy
4,572
+347
+8% +$162K 0.02% 782
2025
Q3 		$1.77M Buy
4,225
+715
+20% +$240K 0.01% 899
2025
Q2 		$1.01M Sell
3,510
-588
-14% -$176K 0.01% 1187
2025
Q1 		$1.26M Buy
4,098
+77
+2% +$26.4K 0.01% 955
2024
Q4 		$1.42M Buy
4,021
+735
+22% +$270K 0.01% 866
2024
Q3 		$1.18M Buy
3,286
+1,233
+60% +$417K 0.01% 959
2024
Q2 		$654K Buy
2,053
+147
+8% +$38.9K 0.01% 1184
2024
Q1 		$438K Sell
1,906
-118
-6% -$26.6K ﹤0.01% 1321
2023
Q4 		$468K Sell
2,024
-167
-8% -$38.5K 0.01% 1239
2023
Q3 		$495K Buy
2,191
+511
+30% +$118K 0.01% 1207
2023
Q2 		$371K Buy
1,680
+148
+10% +$32.8K ﹤0.01% 1323
2023
Q1 		$343K Buy
+1,532
New +$378K ﹤0.01% 1291

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Brinker Capital Investments's UTHR Position: Q2 2026 in Review

Brinker Capital Investments reduced its United Therapeutics (UTHR) stake by 1.5% in Q2 2026, selling an estimated $36K and leaving 4,176 shares worth $2.26M. The position accounts for 0.02% of the portfolio, ranked #730.

Brinker Capital Investments first reported a position in UTHR in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.51M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Brinker Capital Investments held 4,176 shares of United Therapeutics worth $2.26M as of Q2 2026.
  • Brinker Capital Investments sold 64 United Therapeutics shares in Q2 2026, an estimated $36K.
  • United Therapeutics made up 0.02% of Brinker Capital Investments's portfolio in Q2 2026, its #730 holding.
  • Brinker Capital Investments first reported a position in United Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Brinker Capital Investments's United Therapeutics position peaked at $2.51M in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.